Cargando…

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance

A series of triple action Pt(iv) prodrugs was designed to test the hypothesis that multi-action compounds, where each bioactive moiety intervenes in several cellular processes, might be more effective than a single agent at killing cancer cells. In particular, “triple action” Pt(iv) derivatives of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petruzzella, Emanuele, Sirota, Roman, Solazzo, Irene, Gandin, Valentina, Gibson, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal Society of Chemistry 2018
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944384/ https://www.ncbi.nlm.nih.gov/pubmed/29780561 http://dx.doi.org/10.1039/c8sc00428e

Ejemplares similares

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
por: Raveendran, Raji, et al.
Publicado: (2016)

A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: A Dual-Acting Weapon for Targeting DNA in Cancer Cells
por: Montagner, Diego, et al.
Publicado: (2018)

Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position
por: Tolan, Dina, et al.
Publicado: (2016)

Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity
por: Ahmedova, Anife, et al.
Publicado: (2023)

Lipophilic Fe(III)-Complex with Potent Broad-Spectrum Anticancer Activity and Ability to Overcome Pt Resistance in A2780cis Cancer Cells
por: Abeydeera, Nalin, et al.
Publicado: (2023)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration
por: Barbanente, Alessandra, et al.
Publicado: (2022)

Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)–Pt(IV) Conjugate
por: Scoditti, Stefano, et al.
Publicado: (2022)

Special Issue “Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0”
por: Gandin, Valentina, et al.
Publicado: (2023)

DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds
por: Mu, Meilin, et al.
Publicado: (2022)

Development of Novel Pt(IV)-Carbohydrate Derivatives as Targeted Anticancer Agents against Osteosarcoma
por: Moynihan, Eoin, et al.
Publicado: (2023)

pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma
por: Xia, Hongping, et al.
Publicado: (2016)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents
por: Gandin, Valentina, et al.
Publicado: (2015)

New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents
por: Luo, Bingling, et al.
Publicado: (2017)

Facile Synthesis of a Pt(IV) Prodrug of Cisplatin and Its Intrinsically (195m)Pt Labeled Analog: A Step Closer to Cancer Theranostic
por: Sharma, K. Shitaljit, et al.
Publicado: (2021)

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates
por: Novohradsky, Vojtech, et al.
Publicado: (2017)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity
por: Baburajeev, C. P., et al.
Publicado: (2017)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines
por: Sirota, R., et al.
Publicado: (2016)

Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies
por: Del Genio, Valentina, et al.
Publicado: (2022)

Pd(II) and Pt(II) Trinuclear Chelates with Spermidine: Selective Anticancer Activity towards TNBC-Sensitive and -Resistant to Cisplatin
por: Vojtek, Martin, et al.
Publicado: (2023)

Anticancer/Antiviral Agent Akt Inhibitor-IV Massively Accumulates in Mitochondria and Potently Disrupts Cellular Bioenergetics
por: Meinig, J. Matthew, et al.
Publicado: (2014)

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
por: Zheng, Hongping, et al.
Publicado: (2017)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells
por: Kostrhunova, Hana, et al.
Publicado: (2023)

Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study
por: Ratzon, Einav, et al.
Publicado: (2016)

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity
por: El-Damasy, Ashraf K., et al.
Publicado: (2023)

Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents
por: Majcher, Urszula, et al.
Publicado: (2018)

Comprehensive Vibrational Spectroscopic Investigation of trans,trans,trans-[Pt(N(3))(2)(OH)(2)(py)(2)], a Pt(IV) Diazido Anticancer Prodrug Candidate
por: Vernooij, Robbin R., et al.
Publicado: (2016)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors
por: Kato, Noriyasu, et al.
Publicado: (2011)

Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer
por: Kwon, Ahreum, et al.
Publicado: (2020)

Encapsulation of Pt(iv) prodrugs within a Pt(ii) cage for drug delivery
por: Zheng, Yao-Rong, et al.
Publicado: (2015)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
por: Gomez-Roman, Natividad, et al.
Publicado: (2015)

A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities
por: Wang, Juan, et al.
Publicado: (2021)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin
por: Granit, Avital, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ncr19mcionse67i77talphbv1s